BerandaMOLN • SWX
add
Molecular Partners AG
Tutup sebelumnya
CHFÂ 3,26
Rentang hari
CHFÂ 3,26 - CHFÂ 3,33
Rentang tahun
CHFÂ 2,71 - CHFÂ 4,14
Kapitalisasi pasar
132,03Â jt CHF
Volume Rata-Rata
33,09Â rb
Rasio P/E
-
Hasil dividen
-
Bursa utama
SWX
Berita pasar
Keuangan
Laporan Laba Rugi
Pendapatan
Penghasilan bersih
| (CHF) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | — | — |
Biaya operasional | 4,48Â jt | -16,15% |
Penghasilan bersih | -12,65Â jt | -12,62% |
Margin laba bersih | — | — |
Penghasilan per saham | -0,36 | -20,00% |
EBITDA | -12,44Â jt | 14,47% |
Tarif pajak efektif | -0,03% | — |
Neraca
Total aset
Total liabilitas
| (CHF) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 93,06Â jt | -37,73% |
Total aset | 102,11Â jt | -35,59% |
Total liabilitas | 21,77Â jt | 28,90% |
Total ekuitas | 80,33 jt | — |
Saham yang beredar | 37,41 jt | — |
Harga terhadap nilai buku | 1,52 | — |
Tingkat pengembalian aset | -29,56% | — |
Tingkat pengembalian modal | -34,98% | — |
Arus Kas
Perubahan kas bersih
| (CHF) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Penghasilan bersih | -12,65Â jt | -12,62% |
Kas dari operasi | -11,15Â jt | 15,49% |
Kas dari investasi | 11,95Â jt | 365,95% |
Kas dari pembiayaan | -300,00Â rb | -101,96% |
Perubahan kas bersih | 294,00Â rb | 115,65% |
Arus kas bebas | -6,65Â jt | -4,92% |
Tentang
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Didirikan
2004
Karyawan
134
